FDA extends review of BioMarin's hemophilia A gene therapy
The US drug authority first asked for more data for hemophilia A treatment Roctavian, and now it wants more time to process it.
by albert rønning-andersson, translated by daniel pedersen
The US Food and Drug Administration (FDA) says it will extend its review of hemophilia A treatment Roctavian (valoctocogene roxaparvovec), reports the drug’s maker, BioMarin, in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves hemophilia drug from Sobi and Sanofi
For subscribers
.jpg)
BioMarin's dwarfism drug going through growth spurt
For subscribers
.jpg&w=384&q=75)
